EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSEBUG00000001227
Gene Symbol: EGLN1
1 Cross references
238 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSEBUG00000007243
Gene Symbol: ESRRG
1 Cross references
253 Possible Orthologues:

Exportin 1

Ensembl ID : ENSEBUG00000012580
Gene Symbol: XPO1
1 Cross references
302 Possible Orthologues:

Farnesyl Diphosphate Synthase (Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase)

Ensembl ID : ENSEBUG00000009001
Gene Symbol: FDPS
1 Cross references
269 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSEBUG00000010687
Gene Symbol: FDFT1
1 Cross references
223 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSEBUG00000016337
Gene Symbol: FNTA
1 Cross references
222 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSEBUG00000010490
Gene Symbol: FNTB
1 Cross references
211 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSEBUG00000011922
Gene Symbol: FGFR2
1 Cross references
218 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSEBUG00000012723
Gene Symbol: FOLR
1 Cross references
436 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSEBUG00000009358
Gene Symbol: GABBR2
1 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSEBUG00000011262
Gene Symbol: GABRG1
1 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSEBUG00000003960
Gene Symbol: GABBR1
1 Cross references
267 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).